secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001493152-25-010925
Event type: regulatory
Sentiment:  positive
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotech gets USAN approval for 'ateganosine' as generic name for THIO in NSCLC
--------------------------------------------------------------------------------

- USAN Council approved nonproprietary name 'ateganosine' for lead molecule THIO, a telomere-targeting anticancer agent.
- Naming is an essential step in FDA approval process for THIO in advanced non-small cell lung cancer (NSCLC).
- MAIA will retain THIO name for clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).
- No financial terms disclosed; no change in guidance or operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225010925/0001493152-25-010925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225010925/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer